MannKind vs Insulet: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MannKind Corp (MNKD)

Q3 20269 Jul – 6 Aug 2026

▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.

July 20269 Jul – 6 Aug 2026

▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.

Latest9 Jul – 6 Aug 2026

▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.

Insulet Corporation (PODD)

Q3 202619 Jun – 6 Aug 2026

▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.
Highlights a key positive development that could support future revenue.
Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.
Shows ongoing strong performance of the core product.
FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.
A major regulatory setback with potential financial and reputational impact.
Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.
Directly impacts investor expectations and stock valuation.

July 202619 Jun – 6 Aug 2026

▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.
Highlights a key positive development that could support future revenue.
Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.
Shows ongoing strong performance of the core product.
FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.
A major regulatory setback with potential financial and reputational impact.
Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.
Directly impacts investor expectations and stock valuation.

Latest20 Jul – 6 Aug 2026

▼3

Insulet's U.S. Type 2 Weakness and Legal Woes Weigh on Outlook

Securities fraud class action expands with multiple law firm filings Several law firms filed or reminded investors of a securities fraud class action alleging Insulet misled about Omnipod safety and manufacturing. The August 31 lead plaintiff deadline keeps legal risk in focus, which can pressure the stock as investors weigh potential costs and reputational damage.
This is a new legal development that adds to regulatory risk and could hurt investor confidence.
Insulet cuts 2026 revenue growth guidance on weak U.S. Type 2 retention Insulet lowered its 2026 revenue growth outlook to 20-22% from a prior forecast, citing lower-than-expected use and retention among U.S. Type 2 diabetes customers. Although Q2 revenue beat estimates, the reduced guidance signals weaker future demand, which pushes the stock down.
This is a new guidance cut that directly reduces expected future revenue and earnings.
JPMorgan downgrades Insulet to Neutral, slashes price target to $152 JPMorgan downgraded Insulet to Neutral from Overweight and cut its price target to $152 from $275, citing slowing U.S. growth, rising Type 2 attrition, and competition. The downgrade reflects a more cautious view on 2027, which can lead to selling pressure and lower valuation.
This is a new analyst downgrade that directly impacts investor sentiment and valuation.

19 Jun – 13 Jul 2026

▼2▲1

Insulet's strong sales offset by FDA Class I recall and fraud lawsuit

Next-gen Omnipod 6 shows strong trial results Insulet reported positive clinical trial results for its next-generation Omnipod 6 automated insulin delivery system and a fully closed-loop system for type 2 diabetes. The trial showed up to 50% more automated insulin delivery and fewer manual boluses. This innovation could drive future demand and support long-term growth, pushing the stock up.
New product pipeline news that could boost future revenue and investor confidence.
FDA Class I recall of Omnipod devices The FDA classified a recall of certain Omnipod 5, DASH, and Eros insulin pumps as Class I, the most serious type, due to a cannula tear that can cause insulin leakage and under-delivery. This raises safety concerns, may lead to regulatory scrutiny, and could hurt sales and reputation, pushing the stock down.
A major regulatory setback that directly threatens patient safety and future revenue.
Securities fraud class action lawsuit filed A securities fraud class action lawsuit alleges Insulet misled investors about product safety and manufacturing quality. The lawsuit follows two product corrections in 2026 that caused stock drops. Legal costs and potential damages could weigh on the stock, and the lawsuit may keep investors cautious.
New legal risk that could result in financial penalties and further erode investor trust.
Strong Omnipod 5 momentum vs. competition and macro headwinds Omnipod 5 continues to grow rapidly, with 33% revenue growth and a 25% larger customer base. However, intensifying competition and higher raw material and shipping costs from the Middle East conflict could limit profit margins. The strong demand supports the stock, but these headwinds may cap gains.
Balances the positive sales momentum against real pressures that could affect profitability.